Cancer nanomedicine meets immunotherapy: opportunities and challenges

Qingxue Sun, Xiangyang Bai, Alexandros Marios Sofias, Roy van der Meel, Eduardo Ruiz-Hernandez, Gert Storm, Wim E. Hennink, Bruno De Geest, F. Kiessling, Hai-jun Yu, Twan Lammers (Corresponding author), Yang Shi (Corresponding author)

Research output: Contribution to journalReview articleAcademicpeer-review

15 Citations (Scopus)
17 Downloads (Pure)

Abstract

Cancer nanomedicines have shown promise in combination immunotherapy, thus far mostly preclinically but also already in clinical trials. Combining nanomedicines with immunotherapy aims to reinforce the cancer-immunity cycle, via potentiating key steps in the immune reaction cascade, namely antigen release, antigen processing, antigen presentation, and immune cell-mediated killing. Combination nano-immunotherapy can be realized via three targeting strategies, i.e., by targeting cancer cells, targeting the tumor immune microenvironment, and targeting the peripheral immune system. The clinical potential of nano-immunotherapy has recently been demonstrated in a phase III trial in which nano-albumin paclitaxel (Abraxane®) was combined with atezolizumab (Tecentriq®) for the treatment of patients suffering from advanced triple-negative breast cancer. In the present paper, besides strategies and initial (pre)clinical success stories, we also discuss several key challenges in nano-immunotherapy. Taken together, nanomedicines combined with immunotherapy are gaining significant attention, and it is anticipated that they will play an increasingly important role in clinical cancer therapy.
Original languageEnglish
Pages (from-to)954-958
Number of pages5
JournalActa Pharmacologica Sinica
Volume41
Issue number7
Early online date17 Jun 2020
DOIs
Publication statusPublished - Jul 2020

Keywords

  • clinical translation
  • combination therapy
  • immunotherapy
  • nanomedicine
  • targeting

Fingerprint

Dive into the research topics of 'Cancer nanomedicine meets immunotherapy: opportunities and challenges'. Together they form a unique fingerprint.

Cite this